POLISH FINANCIAL SUPERVISION AUTHORITY

Current report no. 20 / 2019

Date of preparation: **2019-07-01**

Abbreviated name of the issuer:

MABION S.A.

Subject

Receipt of the second round of questions in the MabionCD20 registration procedure at the European Medicines Agency

Legal basis:

Article 17(1) MAR - Confidential information.

Content of the report:

Referring to current report no. 10/2019 of 24 April 2019 and previous reports concerning the marketing authorisation application submitted to the European Medicines Agency (EMA) by Mabion S.A. (“Company”) for a medicine under the working name MabionCD20, the Management Board of the Company informs that on 1 July 2019 it received the second round of questions from the EMA under the drug registration procedure (Day 180).

This is a typical stage of the EMA registration procedure and it is included in the Company's schedules, so they remain unchanged. The Company will now proceed to the analysis of questions and to drawing up answers, about the submission of which it will inform in a separate current report.